The U.S. Department of War has awarded Flagship Pioneering a $47 million contract over five years to develop medical countermeasure technologies against emerging threats. According to the release cited by Fierce Biotech, the funding begins with programs at two Flagship-founded companies, Apriori Bio and Prologue Medicines, and leaves room to advance additional projects with Flagship.
A medical countermeasure, as described in the source, is an FDA-regulated product that may be used during a potential public health emergency tied to a biological, chemical or nuclear attack, or a naturally occurring emerging disease. That can include biologics such as vaccines or antibody treatments, drugs such as antivirals and antitoxins, and devices such as diagnostic tests or personal protective equipment.
Program Focus
The contract sits within the Department of War's OnTarget program, which is managed by the joint science and technology office inside the department's chemical and biological defense program. The initiative is focused on broad-spectrum countermeasures against emerging threats, precision delivery technologies, toxin-neutralizing platforms, novel approaches to immune enhancement, and the use of AI and machine learning to optimize medical countermeasures.
That framing matters because the award is not centered on one late-stage asset. Instead, it backs enabling technologies that could feed multiple biodefense programs, giving the department optionality across threat types.
The Initial Company Set
Apriori Bio, founded by Flagship in 2020, develops vaccines using AI and machine learning to predict viral evolution. Its Octavia platform profiles viruses based on their current and future ability to evade the immune system and is designed to provide a view of a virus' evolutionary potential.
Prologue Medicines is focused on understanding the viral proteome and identifying and programming proteins for treating diseases. Under OnTarget, the program seeks to use Prologue's Delve platform, which combines computation and high-throughput biology to identify proteins with advanced characteristics for immunomodulatory protein discovery.
The signal from the award is that the Department of War is funding platform capabilities that may improve preparedness speed and target selection quality before a crisis forces product-specific decisions. For Flagship, the contract also extends a familiar venture model into government-backed biodefense work, with two portfolio companies gaining an initial entry point and the possibility of follow-on programs.
